[PMH35] Sertindole in the treatment of schizophrenia in Poland: a cost analysis

[PMH35] Sertindole in the treatment of schizophrenia in Poland: a cost analysis

2007 Value in health

Hansen, K. | Sapin, C. | Toumi, M. | Volume: 10, Issue: 6, Pages: A298, Schizophrenia, analysis, Risperidone, methods, utilization,

OBJECTIVES: To evaluate the clinical outcomes and costs of
sertindole versus risperidone in the treatment of schizophrenia
in Poland, when considering the ECG measurements required
for prescribing sertindole. METHODS: A 6-month cost analysis
of a randomized, double-blind, parallel-group, flexible-dose,
multi-centre study was performed, for which the efficacy and
tolerability of sertindole were directly compared with risperidone.
The health outcomes observed in this clinical trial were
percentage of patients experiencing response (defined as a 50%
reduction on the PANSS); experiencing EPS-related adverse
events (AEs); and experiencing insomnia/agitation as an adverse
event. For the cost analysis these were converted into 6-month
rates and associated with a treatment cost. To estimate the total
cost of treatment of schizophrenia in Poland a survey among 5
Polish clinical experts was conducted assessing the resource utilization
for responding and non-responding patients, and for
treatment of the adverse events. The cost of treatment included
the cost of the antipsychotic agent, the treatment of the adverse
events, and the cost of response or non-response. RESULTS:
The 12-week health outcomes observed in the clinical trial
were: response rates of 42.2% and 32.9% for sertindole and
risperidone, respectively; 19% and 28% of patients experiencing
EPS-related AEs for sertindole and risperidone, respectively;
and 9.3% and 12.4% of patients experiencing insomnia/
agitation as an adverse event for sertindole and risperidone,
respectively. The total estimated 6-month costs of treating a
patient in Poland responding to antipsychotic treatment is
10.046 PLN, and for a non-responding patient 25.929 PLN.
When the health outcomes are extrapolated to 6 months, and
the 6-month costs are applied, the total cost of 6-month treatment
with sertindole is 18.305 PLN as compared with 19.448
PLN with risperidone. CONCLUSION: Sertindole is therefore
a less costly antipsychotic-treatment option in Poland, despite
the additional costs of ECGs (30 PLN).

https://www.doi.org/10.1016/S1098-3015(10)65085-1